An article from
Dive Brief
//
Emerging biotech
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.
Ollin refuels with $330M to back pivotal tests of Vabysmo challenger
One of the year’s largest venture funding rounds comes just after a head-to-head study showed Ollin’s drug — licensed from a China-based developer — had certain advantages over Roche’s eye treatment.
555 words~3 min read
